---
layout: minimal-medicine
title: Bivalirudin
---

# Bivalirudin
### Generic Name
Bivalirudin

### Usage
Bivalirudin is a medication primarily used as an anticoagulant (blood thinner) in patients undergoing percutaneous coronary intervention (PCI), a procedure to open blocked coronary arteries.  Its primary use is in patients with or at high risk of developing acute coronary syndrome (ACS), including ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome (NSTE-ACS), and those with stable ischemic heart disease.  A significant secondary use is in patients with heparin-induced thrombocytopenia (HIT) or HIT/TS (thrombosis syndrome), a serious complication where the body develops antibodies against heparin, a common anticoagulant.  Bivalirudin's use is also being explored in other cardiac surgery scenarios.


### Dosage
Bivalirudin dosage is highly individualized and depends on the specific procedure and the patient's condition.  It's crucial to follow a healthcare provider's instructions precisely.  Dosage is expressed in mg/kg (milligrams per kilogram of body weight) and mg/kg/h (milligrams per kilogram per hour for continuous infusions).  

**PCI:**  A common regimen involves an initial bolus (a single, large dose) followed by a continuous infusion. Dosage varies based on the situation, but a typical regimen might be a 0.75 mg/kg bolus before the procedure, followed by a 1.75 mg/kg/h infusion during the PCI. Post-procedure, the infusion may continue for up to 4 hours.

**Cardiac Surgery (Off-Label Use):** In cardiac surgery for patients with acute or subacute HIT, dosage varies significantly depending on whether the surgery is on-pump (using a heart-lung machine) or off-pump.  On-pump scenarios generally involve higher initial boluses and infusion rates, adjusted to maintain specific activated clotting times (ACTs).  Dosage adjustments are made based on ACT levels during surgery.


**HIT (Off-Label Use):** For treating HIT, Bivalirudin is administered intravenously at a much lower rate, typically starting at 0.15-0.2 mg/kg/h and adjusted to keep the activated partial thromboplastin time (aPTT) within a target range.


**Renal Impairment:** Dosage adjustments are necessary for patients with reduced kidney function (renal impairment). The adjustments are substantial, and the provider will calculate the appropriate dose based on the patient's creatinine clearance (CrCl) level.  Hemodialysis and continuous renal replacement therapy (CRRT) also necessitate further dosage modifications.  

**Pediatric Use:** The safety and efficacy of Bivalirudin in children have not been established.


### Side Effects
**Common Side Effects:**

* Bleeding (minor to major)
* Headache
* Nausea
* Hypotension (low blood pressure)
* Pain at the injection site
* Back pain

**Less Common, but Serious Side Effects:**

* Thrombocytopenia (low platelet count)
* Allergic reactions (including anaphylaxis, a life-threatening allergic reaction)
* Kidney problems (renal failure)
* Intracranial hemorrhage (bleeding in the brain)
* Stent thrombosis (blood clot forming in the stent placed during PCI)


Any new or worsening symptoms, especially unusual bleeding, should be reported immediately to a healthcare professional.


### How it Works
Bivalirudin is a direct thrombin inhibitor. Thrombin is a crucial enzyme in the blood clotting cascade. Bivalirudin directly binds to thrombin, blocking its ability to trigger the formation of blood clots.  This prevents further clot formation and helps to prevent the extension of existing clots, thereby reducing the risk of heart attack and stroke.


### Precautions
* **Allergy:** Bivalirudin should not be used by individuals with known hypersensitivity to Bivalirudin or any components of the formulation.
* **Bleeding:** Bivalirudin significantly increases the risk of bleeding. Patients with a history of bleeding disorders, those on other blood thinners, or those undergoing procedures that increase bleeding risk should be carefully monitored.
* **Renal Impairment:** Dose adjustments are essential in patients with impaired kidney function.
* **Pregnancy and Breastfeeding:**  Bivalirudin is a Category B drug during pregnancy.  While no direct harm has been conclusively linked to its use, caution is still advised.  It's unknown whether Bivalirudin is excreted in breast milk, so caution is advised during breastfeeding.
* **Drug Interactions:** Bivalirudin can interact with other medications, especially those affecting blood clotting or platelet function.  Always inform your doctor of all medications you are taking.
* **Spinal/Epidural Anesthesia:** Use with caution or avoid use with spinal or epidural anesthesia due to the increased risk of spinal hematoma (bleeding in the spinal cord).



### FAQs

**Q: How is Bivalirudin administered?**
A: Bivalirudin is administered intravenously (IV) either as a bolus injection or as a continuous infusion, depending on the situation and the prescribed dosage regimen.

**Q: How long does it take for Bivalirudin to work?**
A: The onset of action is relatively rapid.  The effects are observed within minutes following administration.  

**Q: How long will I need to take Bivalirudin?**
A: The duration of Bivalirudin treatment varies depending on the medical reason and the medical procedure.  It's usually given for a short period, such as during and immediately after a PCI procedure, or for a longer period in the treatment of HIT.  The duration of therapy is determined by a healthcare professional.

**Q: What should I do if I miss a dose?**
A:  This information cannot provide specific advice.  It is crucial to contact your doctor or healthcare provider immediately if you miss a dose or have any questions regarding your treatment plan.

**Q: How should I store Bivalirudin?**
A:  Consult the specific storage instructions found on the product packaging or your healthcare provider.


**Disclaimer:** This information is for general knowledge and does not constitute medical advice. Always consult a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The information provided here may not cover all possible uses, directions, precautions, warnings, drug interactions, or adverse effects.  The labeling on the medicine package should always be consulted for complete and up-to-date information.
